Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression Lucia Vráblová; Hana Klamová; Ivana Skoumalová; Jana Navrátilová; Romana Janská; Jan Grohmann; Milena Holzerová; Edgar Faber;

Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies Tomasz Sacha; Katarzyna Krawczyk;

Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice Carla Boquimpani; Fernanda Salles Seguro; Gustavo Henrique Romani Magalhães; Ingrid Luise Soares Pinto; Israel Bendit; Jaisson André Pagnoncelli Bortolini; Katia Borgia Barbosa Pagnano; Renato Centrone; Vaneuza Funke;